Biomarker & Intervention Discovery
Lung Cancer
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs3.04MWHO GHE 2021 · all ages
Global DALYs45.38MWHO GHE 2021 · worldwide
US mortality137.1K deaths/yrWHO GHE 2021
Global mortality1.85M deaths/yrWHO GHE 2021 · worldwide
NIH funding$439MFY2025 · RCDC estimate
Funding levelUnderfunded
Spontaneous remissionSpontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for…
Best-intervention remissionNSCLC with driver mutations (EGFR, ALK, ROS1, MET, KRAS G12C): targeted therapy achieves 70-90% response rates; PFS…
Gap sizeVery large between targeted/immunotherapy eligible and chemotherapy-only; large between treated and screened populations
Primary barrieraccess/practice
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for stage I-II with surgery
Best-intervention remission
NSCLC with driver mutations (EGFR, ALK, ROS1, MET, KRAS G12C): targeted therapy achieves 70-90% response rates; PFS 16-19 months with osimertinib (FLAURA2 combination up to 25 months); immunotherapy (pembrolizumab): 5-year OS ~31% in high PD-L1 expressers vs ~16% chemotherapy; SBRT for early-stage inoperable: 80-90% local control at 3 years
Gap size
Very large between targeted/immunotherapy eligible and chemotherapy-only; large between treated and screened populations
Primary barrier
access/practice
Biomarker testing (PD-L1, EGFR/ALK/ROS1 mutations) still not universal; only 5-6% of high-risk smokers undergo low-dose CT screening despite 20% mortality reduction (NLST trial); smoking cessation dramatically reduces incidence but is underfunded
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Lung Cancer” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."